Request for Proposals (RFP) Notice: In Vitro Metabolism & Metabolite Quantification

Notice Number: NOT-DA-15-035

Key Dates
Release Date: May 2, 2014

Related Announcements
None

Issued by
National Institute on Drug Abuse (NIDA)

Purpose

The National Institute on Drug Abuse (NIDA) intends to solicit proposals from qualified businesses to provide in vitro metabolism and permeability determinations for its medications development program in support of the Division of Pharmacotherapies and Medical Consequences of Drug Abuse (DPMCDA). The in vitro metabolism studies for this contract typically include metabolite profiling for interspecies comparison using hepatocytes and microsomes, CYP 450 phenotyping reaction, CYP 450 inhibition, and CYP 450 induction for potential medications. It may also include evaluation of in vitro metabolism by other systems such as hepatic cytosol, hepatic mitochondrial fraction, or Phase II reactions (glucuronidation, sulfation, acetylation, methylation, conjugation with glutathione, conjugation with amino acids). This contract may also provide structure identification of major metabolites by mass spectrometry or nuclear magnetic resonance (NMR). Additional in vitro studies include determination of intestinal and blood-brain barrier permeabilities of new compounds. 

In order to handle substances under the Controlled Substances Act of 1970, it is mandatory that offerors possess a DEA Registration for Chemical Analysis or Research Registration for Schedules II to V and demonstrate the capability to obtain a DEA registration for Schedule I controlled substances.

NIDA anticipates one (1) Indefinite Delivery Indefinite Quantity (Task Order) type contract will be awarded. NIDA plans to issue fixed price task orders.

RFP No. N01DA-15-8919 will be available electronically on or about May 19, 2014. You can access the RFP through the FedBizOpps (URL: http://www.fedbizopps.gov or through the NIDA website at the following address: (URL: http://www.nida.nih.gov/RFP/RFPList.html). All information required for the submission of an offer will be contained in or accessible through the RFP package. Response to the RFP will be due 45 days after the solicitation is issued. NIDA will consider proposals submitted by any responsible offeror.

Based upon market research, the Government is not using the policies contained in Part 12, Acquisition of Commercial Items, in its solicitation for the described supplies or services.  However, interested persons may identify to the Contracting Officer their interest and capability to satisfy the Government’s requirement with a commercial item within 15 days of this notice.

Disclaimer and Important Notes:
This notice is for informational purposes and does not obligate the Government to award a contract or otherwise pay for the information provided in response.

Inquiries

Please direct all inquiries to:

Lisa Bielen
National Institute on Drug Abuse (NIDA)
Telephone: 301-443-6677
Email: lisa.bielen@nih.gov

 

NIH Office of Extramural Research Logo
Department of Health and Human Services (HHS) - Home Page
Department of Health
and Human Services (HHS)
USA.gov - Government Made Easy
NIH... Turning Discovery Into Health®


Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.